dc.contributor.author
Branchi, Federica
dc.contributor.author
Klingenberg-Noftz, Rolf
dc.contributor.author
Friedrich, Kristina
dc.contributor.author
Bürgel, Nataly
dc.contributor.author
Daum, Severin
dc.contributor.author
Buchkremer, Juliane
dc.contributor.author
Sonnenberg, Elena
dc.contributor.author
Schumann, Michael
dc.contributor.author
Treese, Christoph
dc.contributor.author
Tröger, Hanno
dc.contributor.author
Lissner, Donata
dc.contributor.author
Epple, Hans-Jörg
dc.contributor.author
Siegmund, Britta
dc.contributor.author
Stroux, Andrea
dc.contributor.author
Adler, Andreas
dc.contributor.author
Veltzke-Schlieker, Winfried
dc.contributor.author
Autenrieth, Daniel
dc.contributor.author
Leonhardt, Silke
dc.contributor.author
Fischer, Andreas
dc.contributor.author
Jürgensen, Christian
dc.contributor.author
Pape, Ulrich-Frank
dc.contributor.author
Wiedenmann, Bertram
dc.contributor.author
Möschler, Oliver
dc.contributor.author
Schreiner, Maximilian
dc.contributor.author
Strowski, Mathias Z.
dc.contributor.author
Hempel, Volkmar
dc.contributor.author
Huber, Yvonne
dc.contributor.author
Neumann, Helmut
dc.contributor.author
Bojarski, Christian
dc.date.accessioned
2023-07-19T13:05:56Z
dc.date.available
2023-07-19T13:05:56Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/40177
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-39898
dc.description.abstract
Background: A recently developed haemostatic peptide gel for endoscopic application has been introduced to improve the management of gastrointestinal bleeding. The aim of this pilot study was to evaluate the feasibility, safety, efficacy and indication profiles of PuraStat in a clinical setting.
Methods: In this prospective observational multicentre pilot study, patients with acute non-variceal gastrointestinal bleeding (upper and lower) were included. Primary and secondary application of PuraStat was evaluated. Haemoglobin, prothrombin time, platelets and transfusion behaviour were documented before and after haemostasis. The efficacy of PuraStat was assessed during the procedure, at 3 days and 1 week after application.
Results: 111 patients with acute gastrointestinal bleeding were recruited into the study. 70 percent (78/111) of the patients had upper gastrointestinal bleeding and 30% (33/111) had lower gastrointestinal bleeding. After primary application of PuraStat, initial haemostatic success was achieved in 94% of patients (74/79, 95% CI 88-99%), and in 75% of the patients when used as a secondary haemostatic product, following failure of established techniques (24/32, 95% CI 59-91%). The therapeutic success rates (absence of rebleeding) after 3 and 7 days were 91% and 87% after primary use, and 87% and 81% in all study patients. Overall rebleeding rate at 30 day follow-up was 16% (18/111). In the 5 patients who finally required surgery (4.5%), PuraStat allowed temporary haemostasis and stabilisation.
Conclusions: PuraStat expanded the therapeutic toolbox available for an effective treatment of gastrointestinal bleeding sources. It could be safely applied and administered without complications as a primary or secondary therapy. PuraStat may additionally serve as a bridge to surgery in order to achieve temporary haemostasis in case of refractory severe bleeding, possibly playing a role in preventing immediate emergency surgery.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Gastrointestinal bleeding
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
PuraStat in gastrointestinal bleeding: results of a prospective multicentre observational pilot study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s00464-021-08589-6
dcterms.bibliographicCitation.journaltitle
Surgical Endoscopy
dcterms.bibliographicCitation.number
5
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
2954
dcterms.bibliographicCitation.pageend
2961
dcterms.bibliographicCitation.volume
36
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34129089
dcterms.isPartOf.issn
0930-2794
dcterms.isPartOf.eissn
1432-2218